

Unbiased metagenomic detection of RNA viruses for rapid identification of viral pathogens in clinical samples

1 **Anthony D. Kappell^{1*}, Amanda N. Scholes¹, Matthew B. Scholz¹, Nicolette C. Keplinger¹, Leah**
2 **W. Allen¹, Matthew C. Murray¹, Krista L. Ternus¹ and F. Curtis Hewitt¹**

3 ¹ Signature Science, LLC, Austin, Texas, United States of America

4 *** Correspondence:**

5 Corresponding Author

6 akappell@signaturescience.com

7 **Keywords: Nanopore Sequencing, MinION, RNA Virus, Agnostic Sequencing, Metagenomics,**
8 **Respiratory Pathogens, Blood Pathogens, Coronavirus.**

Abstract

9 Unbiased long read sequencing approaches for clinical metagenomic sample analysis holds enormous
10 potential for pathogen detection, including improved detection of unknown, novel or emerging
11 viruses. However, the rapid rate of development in nanopore sequencing and library preparation
12 methods complicates the process of selecting a standardized method for unbiased RNA virus
13 detection. Here, we evaluate multiple sequencing approaches to identify a workflow with sufficient
14 sensitivity, limits of detection, and throughput for potential utilization in a clinical laboratory setting.
15 Four separate library preparation methods for the Oxford Nanopore Technologies MinION sequencer
16 are compared, including direct RNA, direct cDNA, rapid cDNA, and double stranded cDNA. We
17 also establish that depletion of host RNA is not required and can be deleterious for viral RNA
18 detection in some instances when using samples in viral transport media (VTM) or plasma. Using
19 unbiased whole genome amplification following reverse transcription, we achieve limits of detection
20 on the order of 1.95E03 GE/mL of Venezuelan Equine Encephalitis Virus (VEEV) spiked in human
21 plasma. We also report initial detection of 5.43E06 GE/mL of coronavirus 229E spiked into VTM
22 samples containing human background RNA which are expected to decrease significantly during
23 upcoming testing. These metrics were achieved within a 6-plex multiplex reaction, illustrating the
24 potential to increase throughput and decrease costs for relevant sample analysis. Data analysis was
25 performed using EPI2ME Labs framework and open access tools that are readily accessible to most
26 clinical laboratories. Taken together, this work describes an optimized method for unbiased nanopore
27 sequencing and analysis of RNA viruses present in two common clinical matrices.

28 Introduction

29 RNA viruses pose a significant threat to global public health. Beyond the current coronavirus
30 pandemic, filoviruses (e.g., ebolaviruses), alphaviruses (e.g., Venezuelan Equine Encephalitis Virus
31 (VEEV)), and flaviviruses (e.g., Zika virus), among others, cause recurring outbreaks in the Americas
32 and around the world. While transmission pathways and replication numbers vary between them,
33 viruses generally form the most transmissible infectious threats, and beyond vaccines, they have
34 fewer options for treatment and containment following an outbreak. Spillover of zoonotic diseases
35 from animal populations (e.g., bats), which is the likely cause of many recent viral outbreaks,
36 presents a continuing threat.

37 Unbiased, metagenomic sequence-based approaches could lead to early detection of both previously
38 characterized and novel RNA viruses [1]. It has the potential to serve as a hypothesis-free, single, and
39 universal assay for diagnostics of known and novel infectious disease and Emerging Infectious
40 Diseases (EIDs) directly from samples [2–5]. Metagenomics for pathogen detection in public health
41 could overcome many of the current challenges with traditional methods. It offers the power to
42 identify novel or divergent pathogens for which there is no other diagnostic test available, as well as
43 the ability to more rapidly and cost effectively identify known pathogens. Techniques that require
44 serial testing against a list of suspected pathogens or culturing can lead to delayed actionable results
45 especially for slow-growing pathogens, such as *Mycobacterium tuberculosis*, while metagenomic
46 approaches comprise a single test and are increasing in speed as sequencing technologies advance.
47 Although performing multiple tests for known pathogens can become very expensive and time
48 consuming, the declining cost of a single metagenomic test makes it more economically justifiable.
49 These trends of increasing speed and reduced cost are highlighted by nanopore sequencing, which
50 can combine real time sequence analysis with relatively inexpensive, disposable sequencing reagents.

51 Nanopore sequencing for public health threats is well established [6–9], and targeted nanopore
52 sequencing for viral detection has been successful as part of the COVID-19 pandemic response in
53 public health labs [10]. Unlike unbiased metagenomic sequencing, targeted approaches selectively
54 amplify specific sections of viral genomes before sequencing. Rapid nanopore metagenomics
55 workflows, such as cDNA synthesis and direct RNA sequencing, have been established as a
56 foundation for unbiased viral sequencing, but significant work is needed to evaluate and validate the
57 best performing methods to enable the implementation of these promising new tools in public health
58 labs. In this study, we evaluate methods using the Oxford Nanopore MinION sequencing device to
59 detect RNA viruses rapidly and accurately in an unbiased manner. This approach capitalizes on the
60 strengths of the sequencing device by generating sequence data for real time analysis to dramatically
61 shorten the time required to sequence each sample, and critically, enabling workflows for unbiased
62 sequencing to detect novel pathogens and EIDs.

63 **Materials and Methods**

64 **Source Material Quantification and Contrived Sample Preparation**

65 All experiments were performed using VEEV TC-83 (NR-63), SARS-CoV2 (NR-52286), and
66 Human coronavirus (HCoV) 229E (NR-52726). All samples were obtained from BEI Resources. The
67 quantity of RNA in viral stocks (source) was determined using GoTaq Probe (Promega) for VEEV
68 and SARS-CoV2 and GoTaq RT-qPCR (Promega) for Human coronavirus (HCoV) 229E using
69 manufacturer's instructions with an annealing temperature of 55°C. qPCR assays utilized
70 commercially available primers for SARS-CoV-2 (Integrated DNA Technologies Catalog
71 #10006713) and previously established primer sets for VEEV and HCoV 229E. [11] [12] [13] VEEV
72 TC-83 contrived sample was prepared to a working concentration of 1.0×10^{11} Genome Equivalents
73 (GE)/mL by adding 149.15 μ L VEEV TC-83 stock into 1850.85 μ L K₂EDTA human plasma
74 (Gender Unspecified Not Filtered, 5mL (HUMANPLK2-0000285)). A negative control plasma
75 sample was prepared by adding 75.48 μ L PBS to 925.42 μ L human plasma. HCoV 229E contrived
76 sample was prepared by adding 149.15 μ L HCoV 229E stock into 1850.85 μ L SARS-CoV-2 Swab
77 Negative VTM, (Discovery Life Sciences) to a working concentration of 4.08E09 GE/mL. A
78 negative control VTM sample was prepared by adding 45.70 μ L PBS to 454.30 μ L SARS-CoV-2
79 Swab Negative sample in VTM.

80 **RNA Extraction and host rRNA Depletion**

81 RNA from viral stocks, control stocks, and contrived samples were extracted using the Total RNA
82 Purification Plus Micro Kit (Norgen #48500) using manufacturer's instructions and adapting the non-
83 coagulated blood protocol with minor changes of input volume increased to 140 μ L from 100 μ L and
84 Buffer RL increased from 350 μ L to 490 μ L (3.5 volumes). To deplete host rRNA, Illumina's Ribo-
85 Zero Plus rRNA Depletion Kit (#20040526) was used to enzymatically digest ribosomal and globin
86 RNA, following the manufacturer's instructions. Purified contrived RNA and depleted contrived
87 RNA samples were quantified using GoTaq Probe (Promega) using manufacturer's instructions using
88 an annealing temperature of 55°C.

89 **Library Preparation and Sequencing**

90 For testing which library sequencing method worked best, we directly tested Direct RNA (dRNA),
91 Direct cDNA (DcRNA), Rapid, and Double stranded cDNA (dscDNA) sequencing methods. Direct
92 RNA sequencing was performed by using Direct RNA sequencing kit (SQK-RNA002) with the
93 manufacturer's instructions. Starting RNA input of 9 μ L (<500ng) was reverse transcribed using RT
94 adapter and Superscript III (Invitrogen 18080044) and RT adapter resulting in an RNA/DNA hybrid.
95 Direct cDNA sequencing was performed using Direct cDNA Sequencing kit (SQK-DCS109).
96 Briefly, 7.5 μ L purified RNA (<100ng) is used to generate first strand cDNA using Maxima H Minus
97 Reverse Transcriptase (Thermofisher EP0741) using a poly T strand-switching primer. Synthesis of
98 the second strand of cDNA occurred using 2x LongAmp Taq Master Mix (NEB M0287S) before end
99 repair and adapter ligation. For Rapid and dscDNA sequencing, RNA (12 μ L) was transcribed using
100 Maxima H Minus Double-Stranded cDNA Synthesis Kit (Thermofisher K2561) using random
101 hexamers and following the manufacturer's instructions with the minor change of increasing the 1st
102 strand enzyme to 2 μ L. Rapid sequencing was performed using the Rapid sequencing kit (SQK-
103 RAD004) using the manufacturer's instructions. dscDNA libraries were performed using the end
104 repair and adapter ligation of either the Direct cDNA sequencing kit or Ligation sequencing kit
105 (SQK-LSK110), following the manufacturer's instructions. Rapid Barcode sequencing kit (SQK-
106 RBK004) was used for multiplexing rapid libraries. Ligation sequencing kit (SQK-LSK110) and
107 native barcode expansion kit 1-12 (EXP-NBD104) were used for multiplexing dscDNA libraries.

108 All bead cleanups were done on a microfuge tube magnetic separation stand (Permagen). Sequencing
109 of libraries were performed on Oxford Nanopore MinION Mk1B or Mk1C using R9.4.1 flow cells
110 (FLO-MIN106D) or Flongle flow cells (FLO-FLG001) with the Flongle adapter (FLGIntSP). Each
111 flow cell was primed and loaded using manufacturer's instructions. Each run used default settings
112 and ran for approximately 24 hours.

113 **Unbiased cDNA Amplification**

114 Addition of REPLI-g Whole Transcriptomic Analysis (WTA) Single Cell Kit (Qiagen 150063) to the
115 dscDNA and Rapid workflows were examined for increased sensitivity. REPLI-g WTA was used for
116 unbiased cDNA amplification with the following modifications. Briefly, for RNA samples selected
117 for amplification, double-stranded cDNA was transcribed using random hexamers with the Maxima
118 H Minus Double-Stranded cDNA Synthesis Kit and was cleaned using AMPure XP beads. The
119 cleaned cDNA was then denatured at 95°C for 3 min, snap chilled on ice, and amplified using
120 REPLI-g sc Reaction Buffer and SensiPhi DNA polymerase. Amplified samples underwent an
121 AMPure XP bead clean up and digestion using T7 Endonuclease I (NEB M0302L). For effective
122 removal of T7 digested fragments, a custom AMPure XP bead solution was made using PEG 8000
123 50%(w/v) (Fisher Scientific NC1017553). Once cleaned, library construction was performed using
124 the dscDNA or Rapid workflows.

125 **Data Analysis**

126 For each sequencing run, passing reads (default threshold of Q8) were concatenated, and quality
127 control (QC) was performed with by removing all reads that map human before aligning to the viral
128 reference genomes. For validation of viral sequencing and coverage, the target viral genome was
129 selected (e.g., SARS-CoV-2 reference genome, VEEV NC_001449 reference genome, human
130 coronavirus 229E AF304460.1 reference genome). Reads passing QC were aligned to viral genomes
131 using minimap2 with default ont parameters. Alignments were analyzed to determine evenness,
132 depth, and total coverage of the target genome for each library preparation method, which was
133 intended to be used in line with the provisional guidance for sequencing-based diagnostics).
134 Alignments to the viral genome references were used to generate a consensus sequence, BLAST was
135 used to generated additional coverage and percent identity statistics. A presumptive match criteria
136 threshold for evaluating workflows was set based on alignment with known reference genome
137 sequences with greater than 90% identity over 90% or more of the genome. The threshold was
138 determined.

139 **Results**

140 **Library Preparation Method Evaluation**

141 We first sought to characterize genome sequence coverage across four sequencing library preparation
142 workflows. Total RNA was extracted from lysates containing SARS-CoV-2 (heat inactivated) and
143 VEEV. The maximum nucleic acid quantity as specified by manufacturer recommendations was then
144 used as input for each of the four library preparation workflows (Direct RNA (dRNA), Direct cDNA
145 (DcRNA), Rapid, and Double stranded cDNA (dscDNA)). Figure 1 shows the resulting coverage
146 across the two genomes for each library preparation method. (Additional statistics are available in
147 Table S1) The different sequence library preparation workflows produced different levels of
148 coverage of the viral genomes. Because the DcDNA and dRNA methods require the use of a poly-
149 dT primer for reverse transcription, these methods produced a bias for coverage at the 3' end of the
150 genome due to the reliance on the poly-A tail for primer annealing and ligation, respectively. The
151 dscDNA and Rapid method both utilized a random-hexamer for reverse transcription, reducing the
152 bias of specific genomic regions and allowing sequencing of any RNA viruses, not just those with a
153 poly-A tail. As a result, the dscDNA and Rapid methods performed better overall in terms of total
154 genome coverage.

155 When comparing genome sequence coverage between VEEV and SARS-CoV-2, it was apparent that
156 the coronavirus material had lower sequence coverage overall. This discrepancy in read counts could
157 be attributed to lower starting input (~4.23E7 GE SARS-CoV-2 vs. ~8.27E9 GE VEEV). The
158 SARS-CoV-2 material had a higher host background than VEEV based on the abundance of reads
159 mapping to the viral vs. cell culture component of the RNA extracts (data not shown). We
160 hypothesized that, because the SARS-CoV-2 material was heat inactivated, there may have been
161 substantial genome fragmentation and degradation of the SARS-CoV-2 genomes, resulting in lower
162 overall read counts and percentage of passing quality reads. To test this, an alternate, non-inactivated
163 coronavirus culture, Human coronavirus 229E (HCoV 229E), was examined in parallel. Following
164 library preparation using the dscDNA method, it was apparent that HCoV 229E showed markedly
165 higher genome sequence coverage (Figure 1), as well as higher read count and percentage of passing
166 quality reads compared to SARS-CoV-2 (Table S1). This was the case even as HCoV 229E had a
167 similar percentage of reads mapped to the viral genome as SARS-CoV-2 in the respective sequencing
168 runs. Despite the low quality of RNA derived from the heat inactivated SARS-CoV-2 material, the
169 sequencing results demonstrated clear benefits of the random hexamer based reverse transcription

170 methods of dscDNA and Rapid. The Rapid and dscDNA method had greater coverage over the
171 genome compared to DcDNA and dRNA. The dRNA methods using VEEV source material
172 produced low coverage of the genome, while the DcDNA method produced a mean sequencing depth
173 orders of magnitude lower than the Rapid or dscDNA methods using the VEEV source material.

174 Next, we sought to evaluate performance across a number of critical metrics for the performance of
175 metagenomic sequencing assays across the DcDNA, dRNA, dscDNA, and Rapid sequencing
176 workflows. To do this, contrived samples were assembled to mimic human clinical samples. VEEV
177 source material was spiked into human plasma prior to RNA extraction and HCoV 229E was spiked
178 into remnant clinical viral transport media (VTM) samples. Samples were then extracted and
179 sequenced. VEEV samples were sequenced by all four sequencing workflows, while HCoV 229E
180 samples were only sequenced using the top two performing workflows (Rapid and dscDNA) to
181 conserve sequencing reagents.

182 The dscDNA and Rapid methods yield a greater number of reads mapped to VEEV compared to
183 DcDNA and dRNA (Figure 2). dRNA had a greater total number of reads compared to DcDNA and
184 dscDNA but less mapped VEEV reads. The dcDNA method produced the lowest read count of all
185 library preparation methods. The dscDNA and Rapid methods also generated higher quality data
186 suitable for use in mapping and database alignments (Figure 3). Similar to the direct sequencing of
187 VEEV viral extract, the dRNA method resulted in low mean read depth of the genome from RNA
188 extracted from active VEED spiked in human plasma. The DcDNA method using VEEV spiked
189 plasma also had relatively low mean read compared to dscDNA and Rapid methods.

190 With clear performance benefits apparent for the dscDNA and Rapid methods, we utilized these
191 methods to evaluate HCoV 229E detection in a VTM sample background. HCoV 229E was
192 sequenced and detected in a similarly robust manner compared to VEEV in terms of read depth
193 (Figure 2) and read quality and assessment (Figure 3). Summary metrics for both VEEV and HCoV
194 229E spiked samples are shown in Table 1 for the dscDNA and Rapid methods, including non-spiked
195 control samples comprised of RNA extracted from plasma or VTM not containing virus. (Additional
196 metrics are available in Table S2). The table contains the relative genomic equivalence of viral
197 genomes used in each sample input to workflows based on RT-qPCR within the contrived sample
198 indicating the viral load. This value may be an overestimate of certain viral genomic copies,
199 especially for HCoV 229E wherein the RT-qPCR target of the N gene falls within a sub-genomic
200 transcript that may be in greater abundance than the whole genome in the viral lysates used for this
201 study. This sub-genomic transcript at the 3' end of the genome maybe noticeable in Figure 1.

202

203

204

205 **Table 1. Sequencing Summary of Contrived Viral Samples Using dscDNA or Rapid Method**

206

Method	dscDNA	dscDNA	dscDNA	dscDNA	dscDNA	dscDNA	Rapid	Rapid	Rapid	Rapid	Rapid	Rapid
Virus	VEEV	VEEV	229E	229E	None	None	VEEV	VEEV	229E	229E	None	None
Matrices	Plasma	Plasma	VTM	VTM	Plasma	VTM	Plasma	Plasma	VTM	VTM	Plasma	VTM
Replicate	1	2	1	2	1	1	1	2	1	2	1	1
GE in total	1.04E+08	1.04E+08	1.33E+09	1.33E+09	0	0	1.04E+08	1.04E+08	1.33E+09	1.33E+09	0	0
Mean Depth	937.10	2236.30	734.54	3461.83	0	0	15373.00	7265.00	9688.86	7301.84	0	0
Coverage (% minimap2)	99.97	99.99	100.00	100.00	0	0	99.99	99.99	100.00	100.00	0	0
Identity of Coverage (%)	96.34	96.33	99.91	99.91	0	0	96.36	96.35	99.93	99.93	0	0
N50	1,209	1,221	1,535	1,962	658	1317	303	280	349	331	217	261
Longest Alignment length (Kb)	4.62	4.46	6.11	6.87	0	0	2.07	2.08	3.14	2.61	0	0
Total Reads	19,094	46,177	575,045	2,411,913	2047	361,490	1,498,299	911,560	3,313,337	2,788,740	26,785	1,536,316
Passing Quality Reads (%)	80.22	77.97	35.15	13.94	65.5	28.07	78.84	75.00	66.71	74.25	35.89	65.03
Mapped Passed Reads to Virus (%)	69.92	73.00	5.68	17.04	0	0	67.08	57.42	52.22	47.42	0	0
Passing bp (%)	79.99	76.73	63.75	62.63	65.5	28.07	69.36	60.75	66.88	73.04	35.89	60.26

213

214

215

216 **Assessment of Need for Host RNA Depletion from Contrived Samples**

217 Depletion of host RNA within metagenomic samples is commonly used to enrich for viral and other
218 microbial signatures. We examined the effect of host RNA depletion on contrived VEEV samples
219 within a human plasma background. Table 2 summarizes the results from sequencing of RNA
220 recovered following depletion of human ribosomal RNA (cytoplasmic and mitochondrial) and globin
221 RNA (Additional metrics available in Table S3). This included replicate sequencing of the contrived
222 samples using both dscDNA and Rapid library prep methods.

223 In all cases, the host depletion method used caused a decrease in total number of human reads as
224 expected, but the percent of reads passing quality filters and mapping to the viral genome also
225 decreased significantly. This may be due to the method used by the depletion kit, wherein target
226 RNA is enzymatically digested following hybridization by DNA probes complementary to the target
227 sequence. Based on the N50 and the decrease in longest read within dscDNA method, the enzymatic
228 digest likely targeted non-specifically to the total RNA. This non-specific cleavage could be related
229 to the low total RNA input into the reaction or the relatively low abundance of human RNA in the
230 samples. This method and alternative methods for depletion may be necessary for other sample types
231 with high host background (e.g., whole blood), but the relatively low abundance of human RNA
232 within the plasma and VTM samples does not appear to necessitate host RNA depletion.

233 We utilized centrifuge to assign taxonomical classification to the sequenced reads (Figure 4). There
234 were 2- to 3-log decreases in the VEEV genomic material recovered from the samples that were
235 depleted compared to non-depleted. Meanwhile, human RNA was only depleted by 1- to 2-log. There
236 was very little reduction of human RNA depleted within the plasma sample itself.

237

238
239 **Table 2. Sequencing Summary of Host Depletion from Contrived Viral Samples**

Method	dscDNA	dscDNA	dscDNA	Rapid	Rapid	Rapid
Sample	VEEV	VEEV	VEEV	VEEV	VEEV	VEEV
Treatment	None	None	Depleted	None	None	Depleted
GE in total ¹	1.04E+08	1.04E+08	9.50E+07	1.04E+08	1.04E+08	9.50E+07
Post-depletion GE in total	NA	NA	1.60E+07	NA	NA	1.60E+07
Mean Depth	937.10	2236.30	0.73	15,373.00	7265.00	0.03
Coverage (%; minimap2)	99.97	99.99	39.37	99.99	99.99	2.89
Identity of Coverage (%)	96.34	96.33	99.34	96.36	96.35	100.00
N50	1,209	1,221	381	303	280	226
Longest Alignment length (Kb)	4.62	4.46	0.19	2.07	2.08	0.9
Total Reads	19,094	46,177	1,095	1,498,299	911,560	5352
Passing Quality Reads (%)	80.22	77.97	28.95	78.84	75.00	20.59
Mapped Passed Reads to Virus (%)	69.92	73.00	5.36	67.08	57.42	0.18

1 - RNA input to depletion kit is less, all resulting depleted RNA was input for sequencing library

240
241 **Assessment of Sample Multiplexing by Barcoding**

242 There are few approaches for sample multiplexing to reduce per sample sequencing costs. Barcoding
243 for running multiple samples on a single flow cell can reduce time by allowing parallel sample
244 preparations and cost by reducing the number of flow cells needed to process multiple samples.
245 However, multiplexing can also reduce sensitivity by producing fewer sequencing reads per samples
246 or barcode and introduce the potential for cross contamination of sample read pools because of
247 barcode crosstalk. The Rapid method essentially allows the barcodes to be added during tagmentation
248 while the dscDNA method allows the use of the Native Barcoding Kit to ligate indexes to each
249 cDNA molecule.

250 We used the 12-plex based barcoding kits to examine multiplexing of the dscDNA and Rapid
251 methods. Ten of the samples contained duplicate reactions of RNA extracted from human plasma
252 spiked with VEEV at multiple concentrations. The last two samples contained RNA extracted from
253 A549 cells and human plasma. Tables 3 and 4 contain the summary results of sequencing using a 12-
254 plex dscDNA method and Rapid method, respectively.

255 The sensitivity threshold for positive detection was set at > 90% identify over > 90% of the genomic
256 sequence. The multiplex dscDNA method (Table 3) dropped below this threshold with VEEV load at
257 1.04E04 GE of VEEV in plasma with coverages at 88% and 75% for the duplicate library
258 preparations. The multiplex Rapid method (Table 4) showed a similar drop in coverage at this
259 loading but to a greater extent (24% and 34%). (Additional metrics are available in Table S4 and S5
260 for multiplex dscDNA and Rapid methods, respectively)

261 The total read counts produced by the multiplex dscDNA method at 1.04E8 load was comparable to
262 the single-plex of the method at the same loading. In addition, the percent of passing reads,
263 percentage of reads mapped to VEEV, and the mean depth were also comparable. Upon the analysis
264 of the duty-time record for the multiplex and single-plex of dscDNA method (Figure 5), single-plex
265 utilization of the available pores appeared to be low. This low utilization provided additional pores
266 for sequencing for multiplex of additional dscDNA libraries without decreasing read quality and read
267 number.

268 The total number of reads using the Rapid method decreased from millions of reads in the single-plex
269 workflow to tens-of-thousands of reads in the multiplex at the same loading. The percentage of
270 quality passing reads was higher in the multiplex compared to the single-plex, but percentage of
271 mapped reads was lower in the multiplex leading to a reduction in mean depth. Some data was lost
272 due to the inability to assign to a barcode (unclassified). Analysis of the duty-time record for the
273 multiplex and single-plex Rapid method (Figure 5) had comparable percentage of pores actively
274 sequencing, suggesting that the Rapid method in single-plex or multiplex used similar flow cell
275 capacity available for sequencing.

276

277 **Table 3. Sequencing Summary of Multiplex (12 samples) of dscDNA Method**

Method	dscDNA	dscDNA	dscDNA	dscDNA	dscDNA	dscDNA	dscDNA	dscDNA	dscDNA	dscDNA	dscDNA	dscDNA	dscDNA		
Virus or Sample	VEEV	VEEV	VEEV	VEEV	VEEV	VEEV	VEEV	VEEV	VEEV	VEEV	VEEV	A549 RNA	Plasma	Unclassified	
GE in total	1.04E+08	1.04E+08	1.04E+06	1.04E+06	1.04E+04	1.04E+04	1.04E+02	1.04E+02	1.04E+02	1.04E+00	1.04E+00	NA	NA	NA	
Replicate	1	2	1	2	1	2	1	2	1	2	1	2	NA	NA	NA
Mean Depth	1099.25	1354.03	8.08	10.47	2.29	1.59	1.13	1.21	1.71	1.73	0.43	1.39	104.46		
Coverage (% minimap2)	99.98	99.99	99.63	99.67	86.82	72.61	65.61	74.01	70.90	77.67	25.44	78.88	99.97		
Identity of Coverage (%) ¹	96.35	96.33	96.19	96.32	97.99	98.28	98.97	99.12	98.01	98.19	99.00	98.66	96.30		
N50	1574	1410	781	598	571	329	747	470	390	695	1036	520	982		
Longest Alignment length (Kb)	4.85	4.63	3.55	3.48	2.08	2.88	2.21	1.35	2.49	2.23	1.42	2.20	4.22		
Total Reads	18,486	26,217	1,901	3,706	3,818	7,134	2,455	4,633	4,381	3,134	86,795	14,208	72,172		
Passing Quality Reads (%)	80.36	81.36	69.59	60.55	54.45	54.74	69.25	63.44	53.71	69.11	89.13	84.13	20.32		
Mapped Passed Reads to Virus (%)	67.22	66.19	5.06	4.10	1.06	0.44	0.65	0.54	0.68	0.92	0.01	0.13	7.28		
Passing bp (%)	84.32	84.64	41.51	64.06	7.49	57.53	51.25	72.68	17.01	74.56	83.63	85.16	4.16		

1 - Average in cases of multiple mapping from discontinuous coverage

278

279 **Table 4. Sequencing Summary of Multiplex (12 samples) of Rapid Method**

Method	Rapid	Rapid	Rapid	Rapid	Rapid	Rapid	Rapid	Rapid	Rapid	Rapid	Rapid	Rapid	Rapid		
Virus or Sample	VEEV	VEEV	VEEV	VEEV	VEEV	VEEV	VEEV	VEEV	VEEV	VEEV	VEEV	A549 RNA	Plasma	Unclassified	
GE in total	1.04E+08	1.04E+08	1.04E+06	1.04E+06	1.04E+04	1.04E+04	1.04E+02	1.04E+02	1.04E+02	1.04E+00	1.04E+00	NA	NA	NA	
Replicate	1	2	1	2	1	2	1	2	1	2	1	2	NA	NA	NA
Mean Depth	246.63	260.82	2.10	8.50	0.22	0.32	0.33	0.19	0.29	0.56	0.41	0.11	29.96		
Coverage (% minimap2)	99.87	99.98	85.99	99.74	21.95	28.28	27.29	14.76	24.69	45.72	25.92	9.76	99.76		
Identity of Coverage (%) ¹	96.34	96.35	98.41	96.41	99.79	99.80	99.45	99.48	99.71	99.52	99.54	99.23	96.33		
N50	276	304	238	227	232	226	232	226	222	225	234	227	268		
Longest Alignment length (Kb)	3.15	2.79	1.56	1.81	1.21	1.20	1.10	0.92	0.59	1.71	1.15	0.53	2.37		
Total Reads	35907	32043	64791	28077	41866	30055	143979	46633	83828	15697	57872	26880	181789		
Passing Quality Reads (%)	85.64	85.34	86.65	81.28	84.24	82.29	86.37	85.23	83.07	75.55	85.74	84.39	21.95		
Mapped Passed Reads to Virus (%)	17.66	24.10	0.09	1.01	0.01	0.03	0.01	0.02	0.02	0.08	0.02	0.02	1.66		
Passing bp (%)	86.72	86.38	86.63	81.12	83.45	81.39	84.18	84.61	82.16	75.36	87.23	84.20	10.20		

1 - Average in cases of multiple mapping from discontinuous coverage

280

281 **Assessment of Lower Throughput Flongle**

282 We evaluated the flongle flow cell. The flongle has lower throughput and cost compared to the
283 standard flow cell. We evaluated the dscDNA and Rapid method for use on the flongle using RNA
284 extracted from plasma spiked with VEEV. Table 5 shows a summary of sequence results from using
285 flongle in place of a standard flow cell for the dscDNA and Rapid methods. Total read counts were
286 significantly lower for dscDNA and Rapid methods using the flongle compared to the standard flow
287 cell. The dscDNA method had comparable percentage of passing quality reads and mapped reads
288 using the flongle to that of a standard flow cell. The Rapid method using the flongle had a decrease in
289 percentage of passing quality of the reads and mapped reads to that of the standard flow cell.

290 Both methods showed high inactivity of pores on the flongle with high percentage of usage of
291 available pores based on the duty-time report (Figure 7). Interestingly, the low usage of the pores on
292 the standard flow cell by dscDNA suggest that the flongle should provide sufficient sequence depth
293 to align with the standard flow cell in these samples. The utilization of number of pores on the
294 flongle was approximately 32 while the standard flow cell showed early usage at approximately 64
295 and falling quickly to 32. However, the increasing inactivation of pores on the flongle quickly
296 reduced the capacity for both methods and causing low read counts. This high inactivation rate
297 reduced the comparable output of the flongle to the standard flow cell for the dscDNA method.
298 Future iterations of the flongle or luck, as loading often is the cause of pore inactivity, may make the
299 flongle a future option for low input samples such as plasma or VTM.

300 **Table 5. Sequencing Summary of Flongle Use**

Method	dscDNA	Rapid
Virus	VEEV	VEEV
GE in total	1.04E+08	1.04E+08
Mean Depth	619.94	1.22
Coverage (%. minimap2)	99.99	70.37
Identity of Coverage (%)	96.32	99.15
N50	1434	208
Longest Alignment length (Kb)	4189	496
Total Reads	16724	4285
Passing Quality Reads (%)	57.21	20.65
Mapped Passed Reads to Virus (%)	66.71	9.27
Passing bp (%)	54.30	4.23

301

302 **Assessment of Whole Transcriptome Amplification**

303 Because of the low RNA yields contrived VEEV samples in VTM and plasma, we evaluated whole
304 transcriptome amplification (WTA). WTA to increase sequencing material would allow for full
305 utilization of the available pores within a standard flow cell. WTA was examined using a 6-plex
306 barcoding scheme using the native barcoding kit for dscDNA and rapid barcoding kit instead of rapid
307 sequencing kit for the Rapid method. The six samples contained duplicate reactions of RNA
308 extracted from Human plasma spiked with VEEV at decreasing viral load. The genomic equivalency
309 entering the WTA was 8.21E05, E03, and E01.

310 The use of WTA had impacts on both methods. Table 6 and Table 7 contain the sequencing summary
311 for the dscDNA and Rapid methods supplemented with WTA using VEEV, respectively. (Additional
312 metrics are available in Tables S7 and S8). The dscDNA and Rapid method both had increases in
313 total read count compared to the previous multiplex run. WTA greatly increased total read counts for

314 dscDNA compared to single-plex while Rapid increase of total read counts was less, most likely due
315 to their respective pore usages compared to the previous multiplex and single-plex runs. The
316 percentage of passed reads and mapped reads to virus were comparable to previous multiplex runs.
317 There was an increase in N50 in both Rapid and dscDNA methods when using WTA suggesting
318 potentially longer reads. Both methods also had increased coverage of the genome and mean depth at
319 lower VEEV loading. The Rapid method utilizing WTA met threshold (>90% identify over >90% of
320 the genome) as low as 8.21E03 GE improving upon the drop at 1.04E04 GE on the previous
321 multiplex run without WTA. The dscDNA met threshold for all viral loads tested as low as 8.21E01
322 GE improving greatly upon the previous multiplex run drop of sensitivity at 1.04E04 GE. Table 8
323 contains the sequencing summary for dscDNA method supplemented with WTA using HCoV 229E.
324 HCoV 229E was tested as low as 2.29E05 GE viral loading resulting in positive threshold values for
325 identification.

326 Duty-time reports (Figure 8) indicate a high rate of inactivation of pores using the WTA in both
327 dscDNA and Rapid compared to multiplex and single-plex methods without WTA. Both methods
328 showed initial burst of sequencing and utilization of all available pores until inactive channels
329 disrupted productive sequencing. This inactivity was more pronounced in the Rapid method
330 compared to the dscDNA methods, which also contributed to lower total read counts for the Rapid
331 method. The relatively high activity very early with the dscDNA method combined with WTA
332 explains the much higher read count and improvement of coverage and mean depth in samples with
333 lower concentration of spiked VEEV into Human plasma. Interestingly, the barcode crosstalk was
334 lower compared to the previous multiplex run (See Table S7-S9 for unused and unclassified
335 barcodes). This may be due to higher concentration of starting material input to the Rapid Barcoding
336 Kit and the Native Barcoding with Ligation Sequencing Kit. The improved sensitivity and potential
337 for multiplexing samples (at least 6-plex) makes the use of WTA in conjunction with the Rapid and
338 dscDNA methods superior to the methods without WTA.

339 **Table 6. Sequencing Summary of Whole Genome Amplification and dscDNA Method using**
 340 **VEEV (Multiplex of 6 samples)**

Method	dscDNA	dscDNA	dscDNA	dscDNA	dscDNA	dscDNA
Virus or Sample	VEEV	VEEV	VEEV	VEEV	VEEV	VEEV
GE in total	8.21E+05	8.21E+05	8.21E+03	8.21E+03	8.21E+01	8.21E+01
Replicate	1	2	1	2	1	2
Mean Depth	2954.70	3914.28	150.02	137.55	47.41	66.24
Coverage (% minimap2)	99.99	99.97	98.34	98.44	90.33	92.42
Identity of Coverage (%)	96.34	96.37	96.29	96.33	96.94	97.70
N50	3376	2940	2734	3476	3483	3496
Longest Alignment length (Kb)	3.19	2.96	1.84	3.15	1.84	2.86
Total Reads for a Barcode	98649	139714	136040	108623	82638	120026
Percent of Total Reads in Run	10.69	15.14	14.74	11.77	8.96	13.01
Passing Quality Reads (%)	68.51	68.40	69.74	68.21	71.28	68.91
Mapped Passed Reads to Virus (%)	25.89	26.83	0.96	1.01	0.48	0.51
Passing bp (%)	66.86	66.20	67.02	65.28	68.15	66.83

341

342 **Table 7. Sequencing Summary of Whole Genome Amplification and Rapid Method using**
 343 **VEEV (Multiplex of 6 samples)**

Method	Rapid	Rapid	Rapid	Rapid	Rapid	Rapid
Virus or Sample	VEEV	VEEV	VEEV	VEEV	VEEV	VEEV
GE in total	8.21E+05	8.21E+05	8.21E+03	8.21E+03	8.21E+01	8.21E+01
Replicate	1	2	1	2	1	2
Mean Depth	5056.20	5176.32	100.84	114.58	5.31	3.62
Coverage (% minimap2)	99.59	99.27	97.91	97.98	62.48	71.49
Identity of Coverage (%) ¹	96.34	96.34	96.35	96.25	96.97	96.82
N50	2578	2658	2572	2661	2464	2529
Longest Alignment length (Kb)	2.71	2.62	2.10	1.93	1.75	1.89
Total Reads for a Barcode	188566	185313	156451	162121	213392	133602
Percent of Total Reads in Run	15.03	14.77	12.47	12.92	17.01	10.65
Passing Quality Reads (%)	90.06	89.37	89.74	89.05	89.90	89.93
Mapped Passed Reads to Virus (%)	25.43	25.98	0.58	0.60	0.02	0.03
Passing bp (%)	88.52	88.10	88.27	87.40	88.93	89.20

¹ - Average in cases of multiple mapping from discontinuous coverage

344

345

346 **Table 8. Sequencing Summary of Whole Genome Amplification and dscDNA Method using**
 347 **HCoV 229E (Multiplex with 6 samples)**

Method	dscDNA	dscDNA	dscDNA	dscDNA	dscDNA	dscDNA
Virus or Sample	229E	229E	229E	229E	229E	229E
GE in total	2.29E+07	2.29E+07	2.29E+06	2.29E+06	2.29E+05	2.29E+05
Replicate	1	2	1	2	1	2
Mean Depth	3566.62	3050.51	1572.42	1562.44	2059.74	1612.87
Coverage (% minimap2)	99.98	100	99.94	99.92	99.86	99.95
Identity of Coverage (%)	99.89	99.91	99.91	99.92	99.89	99.89
N50	3164	3867	3434	3255	3305	3097
Longest Alignment length (Kb)	3419	3193	3216	314	2822	2340
Total Reads for a Barcode	159507	134289	150470	152969	175653	135563
Percent of Total Reads in Run	13.10	11.03	12.36	12.56	14.42	11.13
Passing Quality Reads (%)	83.53	78.13	80.41	81.00	79.07	80.52
Mapped Passed Reads to Virus (%)	36.50	34.49	18.15	18.32	23.24	23.60
Passing bp (%)	83.03	81.77	80.30	80.22	78.02	79.37

348

349 **Analysis of Clinical Remnant Samples**

350 Clinical remnant samples consisting of respiratory swabbed samples stored in viral transport medium
 351 were subjected to the workflow from viral RNA extraction, library preparation, and bioinformatic
 352 workflow. The clinical samples did not consist of the viruses tested for the validation but are relevant
 353 RNA viruses. The majority of detected viral sequences did not rise to the set threshold of $\geq 90\%$
 354 identity over $\geq 90\%$ of the genome, nor the minimum working mean depth. The only exception was
 355 the detection of human respiratory syncytial virus wildtype strain B1 (RSV) in one of the six
 356 multiplexed samples, at 96.25% identity with 99.32% coverage of the genome (Table 9). (Additional
 357 information is available in Table S10 and S11). This sample also showed 248.9 mean depth, greater
 358 than the working cutoffs of 10 or 15. While RSV was also detected in the other samples, the highest
 359 mean depth was 3.09, well below the mean depth cutoff of 10 utilized to avoid false positives due to
 360 barcode cross talk, as well as the alternative cutoffs determined by the negative control. This result
 361 also highlights the importance of negative controls for the evaluation of potential false positives and
 362 appropriate thresholds. Interestingly, after removal of RSV from the results, barcode17 had human
 363 metapneumovirus as the next top hit in both coverage (29.04%) and mean depth (0.673), including a
 364 percent identity of 92.20% of the covered genome. The detection of human metapneumovirus is the
 365 original detection using current methods. Barcode 21, after removal of RSV, has a Rhinovirus
 366 detection with two genomes at coverage of 17.58% and 16.05% with low mean depth at 0.23 and
 367 6.71, respectively. HRV89 was detected with higher mean depth but marginally lower coverage
 368 percent identity of 79.79%.

369

370

371

372 **Table 9. Clinical Remnant Sample Results with WTA assisted dscDNA method**

Bioinformatic Analysis Call		Sample Key							
Organism	Metric	hMPV	Influenza A	Parainfluenza	SARS-CoV-2	Rhinovirus	RSV	Negative	Positive (GFP)
Human respiratory syncytial virus wildtype strain B1	Coverage	37.79%	24.63%	20.30%	24.47%	32.41%	99.32%	38.38%	6.44%
	Depth	3.08	2.39	1.03	1.27	1.10	249.00	2.34	0.16
Human metapneumovirus isolate CAN97-83	Coverage	29.04%	NA	NA	6.29%	NA	NA	NA	NA
	Depth	0.67			0.06				
Human rhinovirus 89 (HRV89)	Coverage	NA	NA	NA	9.16%	16.05%	NA	NA	NA
	Depth				0.12	4.13			
Rhinovirus C4	Coverage	NA	NA	NA	NA	17.58%	NA	NA	NA
	Depth					0.23			
Respiratory syncytial virus	Coverage	NA	NA	NA	NA	NA	13.59%	NA	NA
	Depth						0.16		

373

374 **1 Discussion**

375 **Potential Time from Sample Extraction to Sequencing Results**

376 Reducing the time required for sample preparation and analysis for RNA or cDNA sequencing are
 377 important factors for public health utilization. The average time required to generate a single sample
 378 library (1-plex) using our unbiased workflow is 9 hrs from raw RNA to loading the MinION flowcell
 379 (Figure 9). Multiplexing (6-plex) on average increases each segment of the hands-on time by 15 min,
 380 while not affecting the incubation time except for End Repair and Ligation. To multiplex, samples
 381 must have a unique barcode ligated before continuing, resulting in a second ligation reaction and
 382 bead cleanup. While this workflow is longer than that of standard workday, there are safe stopping
 383 points can be found throughout our workflow as indicated in Figure 9 with an asterisk to break it over
 384 multiple days.

385 Another limiting factor in sequence analysis is the amount of time needed to generate the necessary
 386 sequence data to identify a potential pathogen within a sample. The process of a DNA sequencing run
 387 can take multiple days to complete on high throughput instruments. Sequencing runs used in this
 388 study were generally conducted for 22 hours to maximize sequence data capture. To evaluate whether
 389 the full 22 hours was needed for viral identification, we evaluated the viral genome coverage and
 390 read depth over time. Figure 10 shows key viral identification metrics from a contrived VEEV
 391 sample in plasma (1.95E03 GE/mL) following WGA in conjunction with the dscDNA method.
 392 Percent identity based on a consensus generated by the mapped reads and Blast+ indicated that the
 393 lowest identity for any covered portion was 97.25%. ‘Mapped Coverage’ measured by minmap2
 394 rising above 90% by 4.25 hrs and maxing at 92.4%, while blast results showed coverage rising to
 395 90% by 2.5 hrs and hitting a maximum of 95%. Based on the ‘Duty time’ record in Figure 8, these

396 were achieved while the capacity of active sequencing pores was still greater than 50% of the flow
397 cell and two-thirds from initiation of the run. This suggests the potential to shorten sequencing run
398 times to < 6 hours depending on the nature of the sample.

399 **Implementing metagenomic assays in clinical laboratories**

400 This study illustrates the potential of metagenomic analysis to public health labs. While the viruses
401 used in this study could be detected by PCR approaches in a rapid and straightforward manner,
402 targeted detection would require *a priori* knowledge of pathogen present or potentially expansive
403 screening using viral detection panels. In the case of a novel, emerging, or uncommon viral pathogen,
404 PCR may fail to identify the agent entirely. This is common in the case of viral sepsis, where a large
405 proportion of cases result in a failure to identify the etiological agent [19]. Thus, it is critical to have a
406 unbiased, metagenomic method capable of identifying novel, emerging, and rare viral threats
407 compatible with widespread utilization in clinical and public health laboratories.

408 This approach does not utilize host RNA depletion. Not only did host RNA depletion not improve the
409 relative proportion of viral sequences, but the method also used actually decreased the amount of
410 viral signature in the sample. This may be due to the relatively low amount of RNA present in these
411 samples and the potential for non-specific activity of the enzymatic digestion approach used. The
412 clinical sample types used in this study were also likely responsible for the low host RNA
413 background. VTM and plasma have lower host background than other sample types, such as whole
414 blood. The application of a genome amplification step supports this observation in that, even
415 following amplification, host background does not appear to overwhelm the viral genome signature
416 within the sample, even at relatively low viral titers.

417 The method described herein does pose limitations in respect to widespread clinical laboratory
418 implementation. While the molecular methods are not onerous, the workflow remains reasonably
419 labor intensive. RNA extractions may be readily automated, and other methods have illustrated
420 approaches for automation of nanopore sequencing library preparation [20,21]. Future development
421 of automated for this method could streamline the workflow and allow higher-throughput analysis
422 based on sample throughput needs. Further optimization could also shorten the amount of time
423 required for DNA sequencing. While this study generally utilized 16-24h sequencing runs, it was
424 clear that the majority of DNA sequencing was completed in the initial few hours following
425 initialization. Further evaluation may reveal shorter sequencing durations that are sufficient to
426 capture viral signature detection without risking false negatives.

427 This method utilizing molecular barcodes to permit multiplexing. This approach has been previously
428 shown to carry some risk of misattribution of barcodes leading to the risk of false positives in one
429 sample due to viral signatures in a different sample in the same sequencing run [5]. While we did
430 observe evidence of barcode “cross-talk,” it was insufficient to lead to false positive detections in
431 negative control samples, even when samples within the same sequencing run had extremely high
432 titers. The potential for barcode cross-talk should be closely monitored in future studies, however, to
433 identify conditions that lead to sufficient cross contamination to lead to potential false positive
434 detection. It is likely that if the high accuracy (HAC) basecaller or alternative highly accurate
435 basecallers can be used the assignment of barcode bin will also improve. Currently, the HAC cannot
436 process reads at a rate to keep up with generation while the fast basecaller can. Crosstalk between
437 barcodes is also likely to improve as ONT iterates barcode length and sequence and R10 flow-cell
438 iteration with related chemistries.

439 Ultimately, before a metagenomic analysis approach can be utilized in clinical laboratories, a more
440 extensive method validation is needed. This process will better establish key assay metrics including
441 sensitivity, specificity, limits-of-detection, and reproducibility. Further analysis should also focus on
442 clinical samples to identify any confounding issues associated with the use of mock clinical samples.

443 **Conclusions**

444 We report an optimal workflow for the unbiased detection of RNA viruses in common clinical
445 matrices. This workflow can support multiplex analysis of up to six samples with approximately 9 (1-
446 plex) to 11 (6-plex) hours of sample preparation, price ranging from \$750 (single-plex) to \$1565 (six-
447 plex), followed by a 10-24 hour sequencing run. The assay can detect viral genomes extracted from
448 human plasma or VTM following a nasal/throat swab with as little as 1.95E03 GE/mL.
449 Bioinformatics analysis is currently tailored toward target pathogens but is readily scalable to a pan-
450 viral assessment to enable unbiased viral signature detection, including homology assessment to
451 identify novel or emerging variants. This data supports the implementation of a sensitive, medium
452 throughput assay capable of unbiased detection of clinical threats in public health laboratories.

453 **Additional Requirements**

454 For additional requirements for specific article types and further information please refer to “Article
455 types” on every Frontiers journal page.

456 **Conflict of Interest**

457 The authors declare that the research was conducted in the absence of any commercial or financial
458 relationships that could be construed as a potential conflict of interest.

459 **Author Contributions**

460 All authors have read and approved the manuscript. Conceptualization: ADK, KLT, MBS, FCH.
461 Data curation: ADK, MBS, NCK. Laboratory analysis: ANS, NCK, MCM, ADK, LWA. Funding
462 acquisition: ADK, FCH, KLT. Data analysis: ADK, ANS, MBS, NCK, KLT, FCH. Project
463 administration: ADK, FCH. Writing – original draft: ADK, ANS, MBS, NCK, FCH. Writing –
464 review & editing: ADK, ANS, MBS, NCK, LWA, MCM, KLT, FCH.

465 **Funding**

466 This work was supported by the Centers for Disease Control and Prevention’s investments to combat
467 antibiotic resistance under contract number 75D30121C12250.

468 **Acknowledgments**

469 The authors would like to thank Leslie Parke for oversight and project management for this effort.
470 The authors would also like to thank Jim Gibson for his assistance creating the workflow figure and
471 Maddie Pont for her technical review. This work appears in the preprint .

472 **1 Data Availability Statement**

473 The datasets generated during this study for this study can be found in our NCBI BioProject
474 [Update].

475 **List of abbreviations [Update]**

476 DNA: Deoxyribonucleic Acid

477 cDNA: Copy DNA

478 dcDNA: Direct Copy DNA

479 DscDNA: Double Stranded cDNA

480 EID: Emerging infectious Diseases

481 GE: Genome Equivalents

482 HAC: High Accuracy Basecalling

483 HCoV: Human CoronaVirus

484 QC: Quality Control

485
486 qPCR: Quantitative Polymerase Chain Reaction

487 RNA: Ribonucleic Acid

488 dRNA: Direct RNA

489 rRNA: Ribosomal RNA

490 RT: Reverse Transcription

491 VEEV: Venezuelan Equine Encephalitis Virus

492 VTM: Viral Transport Media

493 WTA: Whole Transcriptome Amplification

494 **2 References [Need review]**

495 [1] N. Sapoval, M. Mahmoud, M. Jochum, Y. Liu, R.A.L. Elworth, Q. Wang, D. Albin, H.
496 Ogilvie, M.D. Lee, S. Villapol, K. Hernandez, I.M. Berry, J. Foox, A. Beheshti, K. Ternus, K.
497 Aagaard, D. Posada, C. Mason, F.J. Sedlazeck, T.J. Treangen, Hidden genomic diversity of SARS-
498 CoV-2: implications for qRT-PCR diagnostics and transmission, *Genome Res.* (2021)
499 gr.268961.120. <https://doi.org/10.1101/gr.268961.120>.

500 [2] R. Schlaberg, C.Y. Chiu, S. Miller, G.W. Procop, G. Weinstock, the Professional Practice
501 Committee and Committee on Laboratory Practices of the American Society for Microbiology, the
502 Microbiology Resource Committee of the College of American Pathologists, Validation of
503 Metagenomic Next-Generation Sequencing Tests for Universal Pathogen Detection, *Arch. Pathol.*
504 *Lab. Med.* 141 (2017) 776–786. <https://doi.org/10.5858/arpa.2016-0539-RA>.

- 505 [3] R.R. Miller, V. Montoya, J.L. Gardy, D.M. Patrick, P. Tang, Metagenomics for pathogen
506 detection in public health, *Genome Med.* 5 (2013) 81. <https://doi.org/10.1186/gm485>.
- 507 [4] K. Bibby, Metagenomic identification of viral pathogens, *Trends Biotechnol.* 31 (2013) 275–
508 279. <https://doi.org/10.1016/j.tibtech.2013.01.016>.
- 509 [5] Y. Xu, K. Lewandowski, S. Lumley, S. Pullan, R. Vipond, M. Carroll, D. Foster, P.C.
510 Matthews, T. Peto, D. Crook, Detection of Viral Pathogens With Multiplex Nanopore MinION
511 Sequencing: Be Careful With Cross-Talk, *Front. Microbiol.* 9 (2018).
512 <https://www.frontiersin.org/article/10.3389/fmicb.2018.02225> (accessed May 31, 2022).
- 513 [6] F.C. Hewitt, S.L. Guertin, K.L. Ternus, K. Schulte, D.R. Kadavy, Toward Rapid Sequenced-
514 Based Detection and Characterization of Causative Agents of Bacteremia, *BioRxiv.* (2017) 162735.
515 <https://doi.org/10.1101/162735>.
- 516 [7] H.P. McLaughlin, J.V. Bugrysheva, A.B. Conley, C.A. Gulvik, B. Cherney, C.B. Kolton,
517 C.K. Marston, E. Saile, E. Swaney, D. Lonsway, A.S. Gargis, T. Kongphet-Tran, C. Lascols, P.
518 Michel, J. Villanueva, A.R. Hoffmaster, J.E. Gee, D. Sue, Rapid Nanopore Whole-Genome
519 Sequencing for Anthrax Emergency Preparedness, *Emerg. Infect. Dis.* 26 (2020) 358–361.
520 <https://doi.org/10.3201/eid2602.191351>.
- 521 [8] J.A. Russell, B. Campos, J. Stone, E.M. Blosser, N. Burkett-Cadena, J.L. Jacobs, Unbiased
522 Strain-Typing of Arbovirus Directly from Mosquitoes Using Nanopore Sequencing: A Field-forward
523 Biosurveillance Protocol, *Sci. Rep.* 8 (2018) 5417. <https://doi.org/10.1038/s41598-018-23641-7>.
- 524 [9] M.R. Lindberg, S.E. Schmedes, F.C. Hewitt, J.L. Haas, K.L. Ternus, D.R. Kadavy, B.
525 Budowle, A Comparison and Integration of MiSeq and MinION Platforms for Sequencing Single
526 Source and Mixed Mitochondrial Genomes, *PLOS ONE.* 11 (2016) e0167600.
527 <https://doi.org/10.1371/journal.pone.0167600>.
- 528 [10] CDCgov/SARS-CoV-2_Sequencing, Centers for Disease Control and Prevention, 2021.
529 https://github.com/CDCgov/SARS-CoV-2_Sequencing (accessed January 12, 2021).
- 530 [11] M.W. Eshoo, C.A. Whitehouse, S.T. Zoll, C. Massire, T.-T.D. Pennella, L.B. Blyn, R.
531 Sampath, T.A. Hall, J.A. Ecker, A. Desai, L.P. Wasieloski, F. Li, M.J. Turell, A. Schink, K. Rudnick,
532 G. Otero, S.C. Weaver, G.V. Ludwig, S.A. Hofstadler, D.J. Ecker, Direct broad-range detection of
533 alphaviruses in mosquito extracts, *Virology.* 368 (2007) 286–295.
534 <https://doi.org/10.1016/j.virol.2007.06.016>.
- 535 [12] A. Vina-Rodriguez, M. Eiden, M. Keller, W. Hinrichs, M.H. Groschup, A Quantitative Real-
536 Time RT-PCR Assay for the Detection of Venezuelan equine encephalitis virus Utilizing a Universal
537 Alphavirus Control RNA, *BioMed Res. Int.* 2016 (2016) 8543204.
538 <https://doi.org/10.1155/2016/8543204>.
- 539 [13] Human coronaviruses 229E and OC43 replicate and induce distinct antiviral responses in
540 differentiated primary human bronchial epithelial cells | *American Journal of Physiology-Lung*
541 *Cellular and Molecular Physiology*, (n.d.).
542 <https://journals.physiology.org/doi/full/10.1152/ajplung.00374.2020> (accessed May 26, 2022).

- 543 [14] H. Li, New strategies to improve minimap2 alignment accuracy, *Bioinformatics*. 37 (2021)
544 4572–4574. <https://doi.org/10.1093/bioinformatics/btab705>.
- 545 [15] H. Li, Minimap2: pairwise alignment for nucleotide sequences, *Bioinformatics*. 34 (2018)
546 3094–3100. <https://doi.org/10.1093/bioinformatics/bty191>.
- 547 [16] C. Camacho, G. Coulouris, V. Avagyan, N. Ma, J. Papadopoulos, K. Bealer, T.L. Madden,
548 BLAST+: architecture and applications, *BMC Bioinformatics*. 10 (2009) 421.
549 <https://doi.org/10.1186/1471-2105-10-421>.
- 550 [17] A.L. Greninger, S.N. Naccache, S. Federman, G. Yu, P. Mbala, V. Bres, D. Stryke, J.
551 Bouquet, S. Somasekar, J.M. Linnen, R. Dodd, P. Mulembakani, B.S. Schneider, J.-J. Muyembe-
552 Tamfum, S.L. Stramer, C.Y. Chiu, Rapid metagenomic identification of viral pathogens in clinical
553 samples by real-time nanopore sequencing analysis, *Genome Med*. 7 (2015) 99.
554 <https://doi.org/10.1186/s13073-015-0220-9>.
- 555 [18] P.J. McMurdie, S. Holmes, phyloseq: An R Package for Reproducible Interactive Analysis
556 and Graphics of Microbiome Census Data, *PLOS ONE*. 8 (2013) e61217.
557 <https://doi.org/10.1371/journal.pone.0061217>.
- 558 [19] G.-L. Lin, J.P. McGinley, S.B. Drysdale, A.J. Pollard, Epidemiology and Immune
559 Pathogenesis of Viral Sepsis, *Front. Immunol*. 9 (2018) 2147.
560 <https://doi.org/10.3389/fimmu.2018.02147>.
- 561 [20] I. Raymond-Bouchard, C. Maggiori, L. Brennan, I. Altshuler, J.M. Manchado, V. Parro, L.G.
562 Whyte, Assessment of Automated Nucleic Acid Extraction Systems in Combination with MinION
563 Sequencing As Potential Tools for the Detection of Microbial Biosignatures, *Astrobiology*. (2022).
564 <https://doi.org/10.1089/ast.2020.2349>.
- 565 [21] J.F. Hess, T.A. Kohl, M. Kotrová, K. Rönsch, T. Paprotka, V. Mohr, T. Hutzenlaub, M.
566 Brüggemann, R. Zengerle, S. Niemann, N. Paust, Library preparation for next generation sequencing:
567 A review of automation strategies, *Biotechnol. Adv*. 41 (2020) 107537.
568 <https://doi.org/10.1016/j.biotechadv.2020.107537>.

569

570

571

572

573 **Figures, tables and additional files**

574

575 Figure 1.

576




Figure 1. Coverage of the viral RNA genomes based on depth of read alignment.

577

578

579

580





Figure 2. Passed and failed reads states of the difference sequencing workflows for contrived viral samples.

581



582

Figure 3. Average read depth (left) and percent passed bp data (right) from the different sequencing workflows.

583

584

585

586

587

588

589




Figure 4. Effect of Depletion on Centrifuge Read Counts to Different Taxonomy.




Figure 5. Duty time record of dscDNA and Rapid Single-plex and Multiplex (Pore-Scan)

591




Figure 6. Duty Time report from dscDNA and Rapid loaded on a flonge.

592

593




Figure 7. dscDNA or Rapid multiplex with and without WGA

595

596




Figure 8. Whole Genome Amplification and dscDNA Method with HCoV 229E and VEEV indicating the Coverage and Identity of Mapped Reads Generated During the Run

597

598